AK104 + gemcitabine + nab-paclitaxel

AK104 + gemcitabine + nab-paclitaxel is an experimental combination regimen composed of AK104 (penpulimab, an anti-PD-1/CTLA-4 bispecific monoclonal antibody), plus gemcitabine (a nucleoside analog antineoplastic agent) and nab-paclitaxel (albumin-bound paclitaxel, a microtubule inhibitor). - **AK104** is a bispecific antibody targeting PD-1 and CTLA-4, aiming to enhance T-cell mediated antitumor immune responses. - **Gemcitabine** is a cytidine analog that induces apoptosis by inhibiting DNA synthesis primarily in S-phase. - **Nab-paclitaxel** is paclitaxel bound to albumin nanoparticles, improving tumor delivery and minimizing solvent-related toxicities. This regimen is being investigated in solid tumors (such as pancreatic or biliary tract cancer) based on the individual drugs’ established or approved use for such cancers[1][2][3][4][5].

Other names

AK104AK-104AK 104penpulimabalbumin-bound paclitaxelnanoparticle albumin-bound paclitaxelpaclitaxel-albumingemcitabine hydrochloride